Macquarie Group Ltd. lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 13.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 378,591 shares of the biopharmaceutical company’s stock after selling 59,556 shares during the period. Macquarie Group Ltd.’s holdings in Gilead Sciences were worth $26,797,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Seizert Capital Partners LLC grew its position in Gilead Sciences by 4.6% during the first quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock worth $42,964,000 after buying an additional 27,547 shares in the last quarter. Investment Centers of America Inc. grew its position in Gilead Sciences by 7.2% during the first quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock worth $1,979,000 after buying an additional 1,958 shares in the last quarter. Fagan Associates Inc. grew its position in Gilead Sciences by 2.6% during the second quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock worth $2,341,000 after buying an additional 845 shares in the last quarter. Dai Ichi Life Insurance Company Ltd grew its position in Gilead Sciences by 7.6% during the second quarter. Dai Ichi Life Insurance Company Ltd now owns 160,025 shares of the biopharmaceutical company’s stock worth $11,327,000 after buying an additional 11,299 shares in the last quarter. Finally, Capital Asset Advisory Services LLC acquired a new stake in Gilead Sciences during the second quarter worth approximately $875,000. Institutional investors own 76.23% of the company’s stock.
A number of equities research analysts recently issued reports on GILD shares. Berenberg Bank set a $96.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research report on Thursday, October 19th. Royal Bank Of Canada started coverage on Gilead Sciences in a research report on Thursday, September 14th. They set an “outperform” rating and a $94.00 price target on the stock. J P Morgan Chase & Co set a $85.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Robert W. Baird reissued an “outperform” rating and set a $87.00 price target on shares of Gilead Sciences in a research report on Tuesday, August 29th. Finally, Wells Fargo & Company reaffirmed a “market perform” rating and issued a $81.00 target price (up previously from $73.00) on shares of Gilead Sciences in a report on Thursday, August 31st. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $85.11.
Gilead Sciences, Inc. (GILD) opened at $74.22 on Friday. The stock has a market capitalization of $96,960.00, a price-to-earnings ratio of 7.65, a P/E/G ratio of -1.23 and a beta of 1.13. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $86.27.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The business had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. Gilead Sciences’s revenue for the quarter was down 13.2% compared to the same quarter last year. During the same period last year, the company earned $2.75 EPS. equities research analysts anticipate that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.80%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s dividend payout ratio is currently 23.66%.
In related news, EVP Gregg H. Alton sold 25,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $82.65, for a total transaction of $2,066,250.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider John F. Milligan sold 220,000 shares of the firm’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 494,999 shares of company stock valued at $37,404,139. 1.30% of the stock is owned by corporate insiders.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.